top of page


Although autoimmune bullous diseases are rare, they have generated many international research and study papers and guidelines. The following represent some of the most frequently mentioned by patients. It is not an exhaustive list by any means. We recommend you investigate further. Please let us know if you think there are any notable absences that we should include.

NHS guidelines

NHS Referral guidelines for specialist care


Rituximab trials

First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial


UK commisioning policies

Clinical Commissioning Policy for the use of Rituximab in immunobullous disease (England)


Rituximab use

Rituximab for the treatment of pemphigus and pemphigoid disease in adults and children (OW10)
(All Wales Therapeutics and Toxicology Centre)



Doxycycline: a first-line treatment for bullous pemphigoid? And Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial


Clinical consensus

The First International Consensus on Mucous Membrane Pemphigoid - Definition, Diagnostic Criteria, Pathogenic Factors, Medical Treatment, and Prognostic Indicators


Research priorities

The top 10 research priorities for the treatment of bullous pemphigoid, mucous membrane pemphigoid and pemphigus vulgaris in the UK: results of a James Lind Alliance Priority Setting Partnership


FDA patient perspectives

The Importance of Patient-Focused Drug Development in Pemphigus and Pemphigoid


bottom of page